-
Capital, M&A & Industry Strategy1 month agoCRO consolidation keeps rolling. What does that mean for pharma?
While M&A expands one-stop shop capabilities at large CROs, pharma companies could face tradeoffs around niche expertise and service continuity.
-
Capital, M&A & Industry Strategy1 month agoIambic files IPO after signing up AbbVie as new partner
In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.
-
Capital, M&A & Industry Strategy1 month agoAmgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 win
An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline...
-
Capital, M&A & Industry Strategy1 month agoMade Scientific acquires cell therapy facility in Pennsylvania, US
The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical...
-
Capital, M&A & Industry Strategy1 month ago
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets
Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich ataxia (FA) portfolio while locking in...
-
Capital, M&A & Industry Strategy1 month agoiNFixion seeks NF1 treatment by enhancing what the body is doing right
The BIO 2026 Start-up Stadium winner targets a rare disease. As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see […] The...
-
Capital, M&A & Industry Strategy1 month ago
How to navigate the IND process and shorten DNA-to-IND timelines to 6 months
Lonza discusses how navigating shorter DNA-to-IND timelines represents a key milestone in inspiring investor confidence. The post How to navigate the IND process and shorten DNA-to-IND...
-
Capital, M&A & Industry Strategy1 month ago
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up to go public.
-
Capital, M&A & Industry Strategy1 month agoTelix-ITM merger aims to create radiopharma juggernaut: Deals Report
BIOCENTURY | DEALSTELIX-ITM MERGER AIMS TO CREATE RADIOPHARMA JUGGERNAUT: DEALS REPORTPlus: GSK-Chimagen; Novartis-Sironax; Roche-Dualitas; and more
-
Capital, M&A & Industry Strategy1 month agoStockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day
Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more...
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
